Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

Inclusion Criteria

• •Written informed consent prior to study specific screening procedures;
• •Favorable index of curative effect of Diffuse Large B Cell Lymphoma confirmed by histological analysis;
• •≥ 18 and ≤ 70 years of age, male or female;
• •Advanced Lymphoma and standard treatments failed;
• •May benefit from anthracycline-based drugs;
• •ECOG performance status of 0-2;
• •More than 4 weeks from the last chemotherapy, more than 4 weeks from the last biotherapy, more than 4 weeks from the last clinical trial drug therapy;
• •Life expectancy of more than 3 months;
• •Sexually active women of childbearing potential must use a medically acceptable form of contraception;
• •Adequate hepatic, renal, cardiac and hematologic functions: leukocyte≥3.5×10\^9/L,neutrophils≥2.0×10\^9/L,platelets≥100×10\^9/L, hemoglobin≥90g/L,creatinine clearance rate≤1.5×ULN, serum bilirubin≤1.5×ULN, ALT≤2.5×ULN(5×for liver metastasis),AST≤2.5×ULN(5×for liver metastasis), alkaline phosphatase≤200 IU/L,Electrocardiogram appeared to be essentially normal, ejection fraction of Heart Doppler ultrasound appeared to be normal.